文献速递脊柱关节炎

Guselkumab联合Golimumab治疗活动性银屑病关节炎的2a期研究24周结果

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study.
PubMed 文献 · Arthritis Rheumatol · 2026-05-11

这项2a期多中心随机双盲概念验证研究纳入TNFi应答不佳的活动性PsA患者,随机接受Guselkumab联合Golimumab(n=59)或Guselkumab单药(n=32)治疗。主要终点第24周MDA未达统计学差异(29%对22%),但ACR50及CRP≥0.3mg/dL亚组的MDA和ACR50均显示联合治疗更优,安全性无新信号。

要点

  • 主要终点MDA未达标(29%对22%,OR 1.4,P=0.557)
  • ACR50联合组优于单药(44%对22%,名义P=0.034)
  • CRP≥0.3mg/dL亚组联合治疗MDA和ACR50显著更优

核心结论

  • 主要终点未达到,但次要终点和探索性分析提示TNFi-IR的PsA患者尤其CRP升高者可能从联合治疗中获益。

研究设计与样本

  • 2a期多中心随机双盲概念验证研究,活动性TNFi-IR PsA患者按2:1随机接受皮下Guselkumab 100mg联合Golimumab 50mg(n=59)或Guselkumab单药(n=32),每4周一次至第20周。

主要发现

  • 第24周MDA联合组29%、单药组22%(OR 1.4,90%CI 0.6-3.3,P=0.557)。
  • ACR50联合组44%、单药组22%(名义P=0.034)。
  • CRP≥0.3mg/dL亚组联合治疗(n=40)与单药(n=22)MDA为32%对5%(OR 12.3,名义P=0.025),ACR50为55%对14%(OR 9.6,名义P=0.003)。
  • 联合组ACR20为66%对44%,ACR70为27%对16%,身体功能改善更优,银屑病、指炎和附着点炎改善相似。
  • 至第36周无新安全性信号,无结核或机会性感染发生。

关键数值与推荐

  • 主要终点为第24周达到MDA。
  • 入组标准为活动性TNFi-IR PsA,压痛/肿胀关节≥3个。
  • 基线中位压痛关节13个、肿胀关节8个,银屑病体表面积3%,23%有指炎。

临床怎么用

  • 对TNFi应答不佳的活动性PsA患者,尤其CRP≥0.3mg/dL者,Guselkumab联合Golimumab可能带来临床有意义的改善。
  • 联合治疗安全性未见新信号,但需进一步研究验证。

局限性

  • 主要终点未达到,部分阳性结果为次要终点或探索性分析。
  • 样本量较小(联合组59例、单药组32例),亚组分析例数更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi-IR). METHODS: Adults with active TNFi-IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) + golimumab (50 mg) combination therapy (n = 59) or guselkumab monotherapy (n = 32) every 4 weeks through week 20. The primary endpoint was week 24 minimal disease activity (MDA) achievement. Additional endpoints included ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70): improvements in psoriasis, dactylitis, and enthesitis; changes in patient-reported physical function; and impact of screening C-reactive protein (CRP) on MDA/ACR50 response. RESULTS: At baseline, participants had a median of 13 tender and 8 swollen joints and psoriatic body surface area of 3%; 23% had dactylitis. At week 24, 29% and 22% of participants achieved MDA with guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively (odds ratio [OR] 1.4 [90% confidence interval 0.6-3.3]; P = 0.557); 44% and 22% achieved ACR50 (nominal P = 0.034). Participants with CRP levels ≥0.3mg/dL (intended enrollment population) receiving combination therapy (n = 40; monotherapy n = 22) had greater odds of achieving MDA (OR 12.3; nominal P = 0.025; 32% vs 5%) and ACR50 (OR 9.6; nominal P = 0.003; 55% vs 14%) at week 24. Combination therapy was associated with higher ACR20 (66% vs 44%) and ACR70 (27% vs 16%) responses and greater physical function improvements than monotherapy. Improvements in psoriasis, dactylitis, and enthesitis were similar across groups. No new safety signals and no tuberculosis/opportunistic infections occurred through week 36. CONCLUSION: Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP levels, could derive clinically meaningful benefits with guselkumab + golimumab combination therapy, with no new safety concerns, warranting further investigation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Scher JU, McInnes IB, Soriano ER, et al. Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study. Arthritis Rheumatol. 2026. PMID: 41878957. doi:10.1002/art.70152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。